What’s Next?
Jazz intends to finance the acquisition with its existing cash reserves and investments, with an expected closing in Q2 2025, pending regulatory approvals and customary closing conditions. Once finalized, Jazz will leverage its development and commercial capabilities to accelerate dordaviprone’s clinical trial progress and market launch.
With the finish line in sight, all eyes are on the FDA’s decision—a potential game-changer in the fight against aggressive brain tumors.
